The prefilled syringes market is estimated to be worth over USD 2.5 billion by 2030

Roots Analysis has announced the addition of "Prefilled Syringes Market (5th Edition), 2020-2030" report to its list of offerings.
BAKERSFIELD, Calif. - April 8, 2020 - PRLog -- Various factors, such as rise in prevalence of chronic disorders, growing preference for self-injection, anticipated growth of biologics (including vaccines) and biosimilars markets, potential applications in pen-injectors and autoinjectors, and the increasing focus on the prevention of needlestick injuries, are likely to drive growth within the prefilled syringes market.

To order this 550+ page report, which features 150+ figures and 290+ tables, please visit this link

Key Market Insights

100 prefilled syringes are presently available / under development
Around 70% of these products have glass barrels. It is worth mentioning that majority (16) of the plastic barrel syringes are fabricated using cyclo olefin polymer.

Around 30 companies claim to manufacture add-on / integrated syringe safety products
Examples of players that manufacture add-on safety devices include (in alphabetic order, no selection criteria) Alfa Corpuscles, Biocorp, Credence Medsystems, Nemera, Schreiner Medipharm and Tip-Top.

In order to gain competitive edge in the market, manufacturers are actively engaged in developing patient friendly products
The report features a detailed competitiveness analysis of the various prefilled syringes, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.

Close to 90 drugs have been approved in combination with prefilled syringes, over the last seven years
Interestingly, majority (53%) of the abovementioned combination products are antibody-based drug candidates. Currently, the next most popular class of therapeutics is vaccines, representing more than 15% of approved prefilled syringe combination products.

110+ clinical candidates are likely to be developed in combination with prefilled syringes in future
The report features insights on the likelihood of over 250+ marketed products and pipeline candidates, being developed in combination with prefilled syringes. Further, we identified 100+ innovator companies that are likely to enter into partnership with prefilled syringe manufacturers in the foreseen future

Currently, the big pharma focus is on developing prefilled combination products for autoimmune disorders
Insights on the initiatives of the top 20 pharmaceutical companies, highlighting their present priorities in terms of therapeutic areas and type of drug product to be developed in combination with prefilled syringes, are available in the full report.

For additional details, please visit

or email (

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091 (

Roots Analysis
Location:Bakersfield - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Roots Analysis News
Most Viewed
Daily News

Like PRLog?
Click to Share